Lokelma approved in Japan for hyperkalaemia
26 March 2020 07:00 GMT Lokelma approved in Japan for the treatment of hyperkalaemia Patients in Japan will benefit from Lokelma's rapid and sustained potassium control AstraZeneca's Lokelma (sodium zirconium cyclosilicate) has been approved in Japan for the treatment of patients with hyperkalaemia (elevated levels of potassium in the blood). The approval by Japan's Ministry of Health, Labour and Welfare was based on positive results from stand-alone studies in Japan and global clinical trial programmes. It was also supported by DIALIZE, a global trial for